CompletedNot Applicable

MAtrix Therapy for Hard-to-heal ChrOnic Wounds

France191 participantsStarted 2022-02-10

Plain-language summary

CACIPLIQ20® is currently a class III CE marked medical device available in various European and non-European countries, and currently primarily used in managing hard-to-heal wounds. This study is a prospective and standardized recording of patients' data followed in real-life conditions to appreciate the benefits of a therapeutic strategy including CACIPLIQ20® use. It also aims at collecting data to follow-up the device's efficacy and safety and estimate its cost-effectiveness.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. a leg ulceration predominantly of venous origin (no ischemia as previously defined) with an area \>10 cm² and/or a duration of at least 5 months,
✓. a leg ulceration of any size or duration, with a documented ischemic lower limb problem,
✓. a foot ulceration of any size or duration, documented as a diabetic foot ulceration (DFU).

What they're measuring

Rate of wound closure

Timeframe: Within 20 weeks after treatment initiation

Trial details

NCT IDNCT05170984

SponsorOrgan, Tissue, Regeneration, Repair and Replacement

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-07-01

View on ClinicalTrials.gov More Chronic Ulcer of Leg or Foot trials